News Makers Recap for 04-26-11 Print E-mail
By BioMedReports.com Staff   
Tuesday, 26 April 2011 18:42
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 26, 2011.

Advanced Cell Technology ("ACT"; OTCBB:ACTC), a leader in the regenerative medicine space, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a keynote lecture at the 3rd International Collaborative Symposium on Stem Cell Research, April 29-30,  in Seoul, South Korea.

Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that John Thero, Amarin's President, will present at the Deutsche Bank 26th Annual Healthcare Conference to be held at the InterContinental Hotel in Boston.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in Boston on Tuesday, May 3, 2011 at 3:30 p.m. ET.  

Cepheid (NASDAQ:CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu.

Compass Biotechnologies Inc. (OTCBB: COBI) is focused on the development and commercialization of generic, biosimilar and bio-better therapeutic products.

Eli Lilly and Company (NYSE:LLY) and Medtronic, Inc. (NYSE:MDT) today announced they have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new  medicine to the brain using an implantable drug delivery system.

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 10th, 2011, at 8:30 AM ET, to discuss its financial results for the first quarter of 2011.

Kendle (Nasdaq:KNDL), a leading, global full-service clinical research organization, today announced it is the recipient of a "Learning! 100" award from Elearning! Media Group, publishers of Elearning! and Government Elearning! magazines.

Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its first quarter 2011 financial results on Tuesday, May 3, 2011 before the financial markets open.

Life Technologies Corporation (NASDAQ:LIFE) today announced results for its first quarter ending March 31, 2011. Non-GAAP revenue for the first quarter was $897 million, an increase of 1 percent over the $887 million reported for the first quarter of 2010.

MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today its results for the three months ended March 31, 2011.

Novavax, Inc. (Nasdaq:NVAX) announced today the appointments of Louis Fries III, M.D., as Vice President, Clinical and Medical Affairs, and Jane Halpern, Ph.D., as Vice President of Regulatory Affairs.

Orexigen® Therapeutics, Inc. (Nasdaq:OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at The American College of Obstetricians and Gynecologists (The College) 59th Annual Clinical Meeting, April 30 – May 4.

Pharmacyclics, Inc. (Nasdaq:PCYC) announced today that it has received a $7 million milestone payment for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier ("Servier") based on an ex-US collaboration agreement signed in April of 2009.

Sangamo BioSciences, Inc. (Nasdaq:SGMO) today reported first quarter 2011 financial results and accomplishments.

Sanofi-aventis (EURONEXT: SAN and NYSE:SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) today announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen [folinic acid (leucovorin), 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival (OS) in the second-line treatment of metastatic colorectal cancer (mCRC).



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter